Pramlintide
Also called Symlin, SymlinPen, Pramlintide acetate.
Pramlintide had FDA-approved products that FDA records now list as discontinued. This page cites 1 source, and the strongest evidence comes from human trials.
- Status
- Approved, now discontinued
- Form
- Pen injection
- Half-life
- Not modeled
- Strongest evidence
- Human trials
- Cited claims
- 1
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Human trials
A 29-week randomized trial in 296 people with type 1 diabetes found smaller post-meal glucose rises and lower weight with pramlintide plus insulin than with placebo plus insulin.
Limits: Both groups had similar HbA1c reductions. Nausea and severe hypoglycemia were more frequent with pramlintide. This adjunct-to-insulin study does not establish a stand-alone obesity treatment or an insulin replacement.
Regulatory status
United States
Symlin is an FDA-approved subcutaneous pramlintide acetate product used with mealtime insulin in patients with type 1 or type 2 diabetes whose glucose control remains inadequate despite optimal insulin therapy. FDA records list all three Symlin presentations as discontinued. Approval does not establish current availability.